O
Ondrej Toman
Researcher at Charles University in Prague
Publications - 5
Citations - 451
Ondrej Toman is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Membrane protein & Imatinib. The author has an hindex of 4, co-authored 5 publications receiving 422 citations.
Papers
More filters
Journal ArticleDOI
Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins
Jiri Petrak,Robert Ivanek,Ondrej Toman,Radek Cmejla,Jana Cmejlova,Daniel Vyoral,Jan Zivny,Chris D. Vulpe +7 more
TL;DR: The identities of differentially expressed proteins identified in human, mouse, and rat tissues published in three recent volumes of Proteomics are compiled and the appearance of the most predominant proteins in the dataset is calculated.
Journal ArticleDOI
DnaK and GroEL chaperones are recruited to the Bacillus subtilis membrane after short-term ethanol stress
Gabriela Seydlová,Petr Halada,Radovan Fišer,Ondrej Toman,A. Ulrych,A. Ulrych,Jaroslava Svobodová +6 more
TL;DR: The objective is to find out membrane tolerance strategy to ethanol in Bacillus subtilis that possesses a powerful system of protection against environmental stresses.
Journal ArticleDOI
Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
Tereza Hrdinova,Ondrej Toman,Jiri Dresler,Jana Klimentova,Barbora Salovska,Petr Pajer,Oldrich Bartos,Vaclava Polivkova,Jana Linhartova,Katerina Machova Polakova,Hana Kabickova,Barbora Brodska,Matyas Krijt,Jan Zivny,Daniel Vyoral,Jiri Petrak +15 more
TL;DR: In this paper, the authors characterized the exosomes released by imatinib-resistant K562 (K562IR) cells and found that these exosomal cargo was subsequently analyzed to identify resistanceassociated markers using a deep label-free quantification proteomic analysis.
Journal ArticleDOI
Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
Ondrej Toman,T. Kabickova,Ondrej Vit,Radovan Fišer,K. Machova Polakova,Jan Zach,Jana Linhartova,Daniel Vyoral,Jiri Petrak +8 more
TL;DR: It is demonstrated that a proteomic approach may be used to characterize a TKI-resistant population of CML cells enabling future individualized treatment options for patients and proposed that Ca2+ homeostasis can be a potential therapeutic target in C ML cells resistant to TKIs.
Journal ArticleDOI
Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts.
TL;DR: To identify therapeutically exploitable “weaknesses” of the TRAIL‐resistant leukemia cells that could be used as molecular targets for their elimination, proteomic (2‐DE) analysis was performed and over 40 differentially expressed proteins were identified.